Skip to main content
. 2024 Jan 5;8:e2300441. doi: 10.1200/PO.23.00441

FIG 4.

FIG 4.

Recommendations on key elements to be provided for a trial using a TITE-CRM design (for rule-based designs, only clinical parameters and trial result reporting are required). DLT, dose-limiting toxicity; ID, identifier; TITE-CRM, time-to-event continuous reassessment method.